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This study investigated long-term behavioral, neurochemical, and neuropharmacological effects of ethanol–(7)-3,4-methylenedioxy-
methamphetamine (MDMA, ecstasy) combinations. Over 4 consecutive days, male Long–Evans rats received 1.5 g/kg ethanol and/or
10mg/kg MDMA, or saline. Rectal temperatures were taken in some rats. Starting 4 days after the last injection, we tested working
memory, sensory–motor coordination, and anxiety. Subsequently, we measured cortical, striatal, septal, and hippocampal monoamines
(last MDMA injection–euthanasia delay: 20 days), or electrically evoked release of serotonin (5-HT) in cortical and hippocampal slices,
and its modulation in the presence of CP 93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrollo[3,2-b]pyrid-5-one) or methiotepin (last MDMA
injection–euthanasia delays: 3–6 weeks). Ethanol attenuated the MDMA-induced hyperthermia, but only on the first day. In the long-
term, MDMA reduced 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) content in most brain regions. The behavioral and neurochemical
effects of the ethanol–MDMA combination were comparable to those of MDMA alone; sensory–motor coordination was altered after
ethanol and/or MDMA. In hippocampal slices from rats given ethanol and MDMA, the CP 93,129-induced inhibition and methiotepin-
induced facilitation of 5-HT release were stronger and weaker, respectively, than in the other groups. This is the first study addressing
long-term effects of repeated MDMA and EtOH combined treatments in experimental animals. Whereas the drug combination
produced the same behavioral and neurochemical effects as MDMA alone, our neuropharmacological results suggest that MDMA–EtOH
interactions may have specific long-term consequences on presynaptic modulation of hippocampal 5-HT release, but not necessarily
related to MDMA-induced depletion of 5-HT. Thus, it is likely that the psycho(patho)logical problems reported by ecstasy users drinking
alcohol are not solely due to the consumption of MDMA.
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INTRODUCTION
The amphetamine derivative (7)-3,4-methylenedioxy-
methamphetamine (MDMA, ecstasy), first patented in
1914 by the company Merck (Parrott et al, 2001), has
become a popular recreational drug among young people,
particularly in the club culture (eg Green et al, 1995, 2003;
Schifano, 2004). Acutely, MDMA causes a rapid release of
serotonin (5-HT) and dopamine (DA) in the brain. This
increase is accompanied by, and is most likely responsible
for, the dose-dependent increase in spontaneous activity in
humans and rodents. In addition, MDMA produces
hyperthermia that can be fatal in rodents, primates, and
humans (Schifano, 2004). Chronic administration of high
doses of MDMA may result in depletion of 5-HT and 5-
hydroxyindoleacetic acid (5-HIAA) in brain regions such as
the hippocampus, cortex, and striatum (Green et al, 2003).
In rats, the magnitude and duration of this decrease may
depend on various factors such as dose, number and
frequency of treatments, and genetically based individual
differences in sensitivity (Green et al, 2003).
In humans, MDMA is frequently taken with other drugs
such as amphetamine, cocaine, cannabis, and ethanol. Such
combinations presumably enhance the subjective effects of
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the drug (eg Hernandez-Lopez et al, 2002; Lora-Tamayo
et al, 2004; Pedersen and Skrondal, 1999; Schifano, 2004),
both pharmacodynamically and pharmacokinetically
(Oesterheld et al, 2004). Owing to its social role and easy
availability, ethanol is frequently taken in combination
with MDMA (eg Lora-Tamayo et al, 2004; Pedersen and
Skrondal, 1999; Schifano, 2004).
In a recent series of experiments in rats (Cassel et al,
2004), we found that ethanol dramatically potentiated
MDMA-induced hyperlocomotor effect. In contrast, ethanol
prevented the hyperpyretic effect of MDMA, at least acutely.
Our findings on the effect of the combination on body
temperature are in line with data reported by Johnson et al
(2004). These authors found that the combination of
ethanol and MDMA resulted in a decrease in body
temperature higher than that observed after administration
of alcohol alone. There are also two studies that address the
interaction between MDMA and ethanol in humans. One
study focused on the immune system (Pacifici et al, 2001),
and the other, on psychomotor performance and subjective
effects (Hernandez-Lopez et al, 2002). Interestingly, in the
latter study, the authors reported longer lasting euphoria
and feelings of well being with combined MDMA and
alcohol, compared to either drug alone, suggesting that
potentiating effects can be perceived subjectively. In all of
these experiments, however, only acute effects of the
combination were investigated.
Considering the toxicity of MDMA for serotonergic
neurons in some species, and the frequent coadministration
of MDMA with other recreational drugs in humans, we were
interested in characterizing possible long-term conse-
quences of repeated coadministration of the drugs at short
intervals. Along this line, Clemens et al (2004) recently
reported that, in rats, MDMA and methamphetamine
administered in combination produced greater adverse
long-term effects on anxiety and resulted in larger
dopaminergic toxicity than either drug alone. Conversely,
Morley et al (2004) found that D9-tetrahydrocannabinol was
able to prevent the acute MDMA-induced hyperthermia,
and interestingly, also to exert partial protection against the
long-term depletion of 5-HT in various brain regions. In
another recent article, Johnson et al (2004) showed that, in
mice, coadministration of ethanol with MDMA resulted in a
four-fold increase in the concentration of MDMA in the
striatum, suggesting that ethanol facilitated MDMA entry
into the brain or, alternatively, reduced either the excretion
or the biotransformation of this drug. Interestingly, in the
same study, ethanol was also found to protect dopaminergic
neurons from the toxic effects of MDMA.
In the present study, which was carried out in rats (a
species in which MDMA has no reported dopaminergic
toxicity; Green et al, 2003), we investigated behavioral,
neurochemical, and neuropharmacological effects of re-
peated treatment with MDMA and ethanol. On 4 con-
secutive days, male Long–Evans rats were treated with
10mg/kg MDMA combined or not with 1.5 g/kg ethanol.
Behavioral testing was performed between 4 and 19 days
after the last injection of the drugs, using T-maze, beam
walking, and elevated plus-maze tests. These tests were
chosen because (i) T-maze alternation was previously used
to assess long-term effects of MDMA (Ricaurte et al, 1993),
(ii) in previous experiments, we found that rats with
serotonergic lesions exhibited impaired locomotor coordi-
nation in the beam-walking task (Lehmann et al, 2000), and
(iii) acutely, MDMA is anxiogenic (Sumnall et al, 2004) and
anxiety-like behavior can be evidenced weeks, and even
months after repeated MDMA injections (eg Bull et al, 2004;
Clemens et al, 2004; McGregor et al, 2003). After behavioral
testing (ie about 3 weeks after the end of treatment), the rats
were killed for examination of 5-HT and catecholamine
function (determination of monoamine concentrations and
transmitter release experiments in brain slices).
MATERIALS AND METHODS
Subjects
In all, 72 adult male Long–Evans rats (3 months; Centre
d’Elevage R Janvier, Le Genest-St-Isles, France) were used.
They were housed individually in transparent Makrolon
cages (42 26 15 cm3) under controlled temperature
(231C) and a 12/12 h light/dark cycle (lights on at 0700).
Food and water were provided ad libitum. After arrival in
the laboratory, the animals were allowed to acclimate to the
laboratory for 1 week before the experiments were started.
All experimental procedures were conducted in conformity
with the institutional guidelines (council directive 87848,
October 19, 1987, Ministe`re de l’Agriculture et de la Foreˆt,
Service Ve´te´rinaire de la Sante´ et de la Protection Animale;
permission 6212 to J-CC and 6714-bis to HJ; NIH
publication, 86-23, revised 1985).
Drugs and Treatment Protocols
Ethanol (20% (w/v)) was prepared from absolute ethanol
diluted in 0.9% NaCl and injected intraperitoneally (i.p.) at
a dose of 1.5 g/kg. At this dose, ethanol typically results in a
blood concentration of about 175mg/dl. MDMA (NIDA,
USA) was diluted in 0.9% NaCl and injected i.p. at a dose of
10mg/kg. The drugs, whether administered alone or in
combination, were injected at a volume of 7.5ml/kg. For the
combined administration, MDMA was dissolved in the 20%
ethanol solution. On four occasions, 24 h apart, rats were
treated with one of the drugs/combination. The acute
pyretic and locomotor responses to these drugs and to their
combination have been considered in a recent experiment
(Cassel et al, 2004), and were not assessed in the present
study, except for body temperature on a randomly selected
series of rats (see below).
The chemicals and drugs used for brain slice superfusion
experiments were obtained from the following sources: 5-
[1,2-3H(N)] hydroxytryptamine creatinine sulfate ([3H]5-
HT, 30.0 Ci/mmol) from Perkin-Elmer, Rodgau, Germany;
6-nitroquipazine maleate from RBI, Biotrend, Ko¨ln, Ger-
many; methiotepin mesylate from Sigma Aldrich GmbH,
Taufkirchen, Germany; and CP 93,129 (3-(1,2,5,6-tetrahy-
dropyrid-4-yl)pyrrollo[3,2-b]pyrid-5-one) was a gift from
Dr Pagani, Pfizer Inc., Groton, USA.
Body Temperature Measurements
Rectal temperature was measured with a Pic indolor Vedo
Flex (Artsana-Grandate, Italy) digital thermometer with a
0.11C precision, and lubricated with Vaseline. Determina-
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tion of the temperature took a maximum of 30 s. The first
measurement was taken 1 h before drug treatment (between
1100 and 1120). The other measurements were made 30,
60, 120, 180, and 300min after drug administration.
The ambient temperature during measurements was of
2370.11C. Group sizes were: SALINE, n¼ 5; EtOH, n¼ 6;
MDMA, n¼ 5; and EtOHþMDMA, n¼ 7. The initial size of
the MDMA group was 7, but two rats died after MDMA
treatment.
Behavioral Evaluations
Two subgroups of rats from each treatment condition were
randomly tested (1) for T-maze alternation and beam-
walking performance (SALINE, n¼ 10; EtOH, n¼ 12;
MDMA, n¼ 10; EtOHþMDMA, n¼ 9) and (2) elevated
plus maze (SALINE, n¼ 7; EtOH, n¼ 8; MDMA, n¼ 7;
EtOHþMDMA, n¼ 9).
Alternation in the T-maze test. Starting 4 days after the last
injection, all rats were tested for spontaneous alternation in
a T-maze (spontaneous meaning in the absence of any food
reward). All testing was conducted between 1200 and 1800.
The apparatus was a gray Perspex T maze (10 cm
high 10 cm wide) with a transparent Perspex roof and a
40-W white lamp located 105 cm above the choice point.
The 45-cm-long stem and 21-cm-long side arms ended in
20-cm-long interchangeable start/goal boxes. Guillotine
doors were located at the entrance to the stem and on each
side arm, thus allowing for the rat to be confined in the start
box or in the chosen arm. For each trial, the rat was first
subjected to a forced run for which it was placed in the start
box for 10 s before the guillotine door was opened. Once the
rat had reached the end of the forced arm (the other arm
being closed), it remained in this arm for 30 s before
another run was allowed (with both arms open). Start and
goal boxes were interchanged with the rat inside. One trial
(one trial consisting in a forced run followed by a test run)
was given each day during 4 days, and two additional trials
were given on the 5th day (4 h apart), so that six possible
alternations were tested for each rat over the 5-day period.
The experimenter was not aware of the rat’s previous
treatment. The variable considered was the percent alter-
nation on the six trials ((number of alternations/6) 100).
Sensory–motor coordination in the beam-walking test.
Starting 10 days after the last injection, this test was also
conducted between 1200 and 1800. Assessment of motor
coordination was performed by placing each rat on a
2 200 cm2 wooden beam, divided into four 50-cm
segments, elevated 80 cm above the floor level, and which
was in contact with the home cage on one extremity. All rats
were trained according to the following protocol: in the first
session, the rats were placed on the beam at 50 cm from the
goal box (ie their home cage) on five consecutive occasions.
In the next session, the rats were placed at 50, 100, 150, and
200 cm from the goal box, successively, with only one run
allowed for each distance. In the third session, the rats were
placed twice at 100 cm and twice at 200 cm from the goal
box. In the fourth session, the rats were placed at 200 cm for
three consecutive runs. On the next day, all rats were tested
for three consecutive trials as in the fourth session and their
performance was rated. For each virtual 50-cm segment of
the beam, the experimenter rated the locomotor behavior a
score of one per segment when the rat traversed the
segment with all paws on the upper surface of the beam.
Conversely, a score of 0 was given for each segment on
which the rat slipped or placed its toes on the side surface of
the beam. The overall score was calculated by adding the
scores of the three runs (maximal score¼ 12). The observer
was not aware of the rat’s previous treatment.
Anxiety in the elevated plus-maze test. In the present
study, anxiety-like behavior was measured in the elevated
plus maze 19 days after the last drug injection. We used
conditions under which rats do not normally avoid entering
the open arm. Each rat was brought individually to the
testing room 45min before the test was started and kept
in the home cage. The elevated plus-maze apparatus was
made of black Plexiglas and consisted of four arms (50 cm
long 10 cm wide) fixed to a central platform (10 10 cm2):
two had 40-cm high walls (closed arms) and two had
1.5-cm high borders in place of the walls (open arms).
The arms crossed at a right angle and the apparatus was
elevated 73 cm above the floor. The testing room was
equipped with four halogen lamps, positioned on the
diagonals of the plus maze (451 from each arm), at an
identical distance from the central platform. For both open
arms, the intensity of the light was 10 Lx. For testing, rats
were placed individually in the center of the maze with their
head facing a closed arm (the same for all rats). Between
each test, the apparatus was wiped clean with a solution of
2.0% cider vinegar. Each test lasted for 5min. The measures
were taken by an experimenter, blind to the treatments, who
observed the rats via a monitor connected to a camera
(fixed on the desk, 300 cm above the floor level). An entry in
a given arm was counted when the rat had completely
entered the arm (four pawsþ tail in the arm). The primary
measures were the number of entries and the time spent in
each arm. Entries and time in the center were also recorded.
These measures enabled us to compute the number of
entries and time spent on open and in closed arms,
respectively. To balance for potential locomotion biases,
the absolute number of entries and time on the open arms
was expressed as a percentage of the total number of entries
in all arms or of the time spent in these arms, respectively
(open/(closedþ open) 100).
Neurochemical Determinations
Tissue preparation. At 20 days after the last injection, some
of the rats from each group of rats tested for spontaneous
alternation and beam walking (SALINE: n¼ 8; EtOH:
n¼ 10; MDMA: n¼ 8; EtOHþMDMA: n¼ 7) were killed
by microwave irradiation (1.5 s; 6.3 kW; Sairem, Villeur-
banne, France) in order to inactivate rapidly brain enzymes.
After decapitation, the brain was extracted and dissected on
a cold plate in order to extract the prefrontal, frontal,
temporal and occipital cortices, the striatum, the septum,
and both hippocampi, which were separated into a dorsal
(septal pole) and a ventral (temporal pole) portion. The left
and right structures from each rat were pooled, weighed,
and kept at 801C until neurochemical determination.
Concentrations of DA, norepinephrine, 5-HT, and 5-HIAA
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were measured using high-performance liquid chromato-
graphy (HPLC) with electrochemical detection. The tissue
samples were prepared for HPLC by homogenization in 1N
formic acid/acetone (18/8.5, vol/vol), and the formic extract
was used for monoamine determinations.
Determination of monoamine concentrations. The mono-
amine concentrations were measured without further
purification. The HPLC system consisted of an ESA liquid
chromatography pump (ESA Inc., Bedford) coupled to an
ESA Coulochem II detector (Eurosep Instruments)
equipped with a 5014 high-performance analytic cell (ESA
Inc., Bedford). The detector potential at the analytic cell was
set at þ 0.4 V. High-performance liquid chromatography
analysis was performed on a C18 Spherisorb ODS2 reverse-
phase column (5 mm pore size, 4.6mm in diameter, 25 cm
long). The mobile phase consisted of 0.1M NaH2PO4,
pH¼ 3, containing 0.1mM/l of EDTA, 1.7mM/l L-octane
sulfonic acid sodium salt, and 10% acetonitrile. The flow
rate was 1ml/min.
5-HT Release
The rats used for the superfusion experiments were those
that were tested in the elevated plus maze. All experiments
started about 3 weeks after the last treatment and were
conducted within a 3-week period. The rats were killed by
decapitation, their brain was quickly removed, and two
regions were dissected out from each hemisphere, namely
the hippocampus and part of the frontoparietal cortex. Only
the dorsal part of both hippocampi and the cortex pieces
were used for superfusion experiments. For this purpose,
they were cut in slices along the septotemporal and
anteroposterior axis, respectively, using a McIIwain tissue
chopper. The slices (350 mm) were separated and washed
three times with a modified Krebs–Henseleit (KH) buffer
and incubated in small plastic Petri dishes containing 2ml
of KH buffer with [3H]5-HT (0.1 mM) for 45min at 371C
under carbogen. The KH solution had the following
composition (in mM): NaCl, 118; KCl, 4.8; CaCl2, 1.3;
MgSO4, 1.2; NaHCO3, 25; KH2PO4, 1.2; glucose, 10; ascorbic
acid, 0.6; Na2EDTA, 0.03; and saturated with carbogen, pH
adjusted to 7.4.
After incubation, the slices from each structure were
washed three times with KH buffer, and transferred into
superfusion chambers (one slice per chamber) with a total
of 12 chambers for the hippocampus and 12 for the cortex
slices (all chambers were identical). As soon as they were in
the chambers, the slices were superfused with oxygenated
KH buffer (371C) at a rate of 1.2ml/min. The superfusion
buffer was supplemented with 6-nitroquipazine throughout
(1 mM). After 15min of superfusion, the slices were
prestimulated by electrical fields (18 rectangular pulses at
3Hz, 2ms, 4 V/chamber, 25–28mA) and, after 32min,
collection of 2-min fractions was started. The release of
[3H]5-HT was induced three times by electrical field
stimulations (360 rectangular pulses at 3Hz, 2ms, 4V/
chamber, 25–28mA) after 36min (S1), 52min (S2), and
68min (S3) of superfusion. Drugs to be tested (the 5-HT1B
receptor agonist, CP 93,129, at concentrations from 0.001 to
1mM, and the mixed 5-HT1A/5-HT1B antagonist, methiote-
pin, at concentrations of 0.1 and 1 mM) were added to the
superfusion medium from 8min before S2 and S3 onwards,
with concentrations increasing from S2 to S3. At the end of
the experiment (ie after 76min of superfusion), the radio-
activity of superfusate samples and slices (dissolved in
300 ml Solvable 350, Perkin-Elmer, Rodgau, Germany) was
determined by liquid scintillation counting.
The tritium outflow was calculated as a fraction of the
tritium content in the slice at the onset of the corresponding
collection period (fractional rate). The basal tritium outflow
in the fraction preceding S1 is given either in absolute terms
(nCi [3H]outflow per 2min) or in relative terms (fractional
rate of [3H]outflow per 2min). The stimulation-evoked
overflow of tritium was calculated by subtraction of the
basal outflow and is shown either in absolute terms (nCi
[3H]overflow) or in relative terms (in percent of the tritium
content of the slice at the onset of the respective stimulation
period). Effects of drugs added before S2 and S3 were
determined as the ratio of the overflow evoked by the
corresponding stimulation period (S2/S1 or S3/S1) and
compared to the appropriate control ratios (no drug
addition before S2 or S3, respectively).
Statistical Analyses
All data were analyzed using analyses of variance (ANOVA).
Where appropriate, ANOVA was followed by pair-wise
comparisons using the Newman–Keuls test (Winer, 1971). It
should be noticed that the significant differences between
MDMA and EtOH rats, which lack on relevance, are not
indicated in the text or the figures. For statistical evaluation
of transmitter release experiments, only the mean values
calculated from up to 12 ‘slice values’ for each individual rat
were used in the ANOVA. Two rats initially included in this
series of experiments died during temperature measure-
ments. From each group of rats tested for spontaneous
alternation and beam walking, two rats were not killed.
RESULTS
Acute Effects of MDMA on Body Temperature
Whatever day was considered, 1 h before drugs/combina-
tion administration, the average body temperature did not
significantly vary among groups (Day 1: 37.970.1; Day 2:
37.570.1; Day 3: 37.770.1; Day 4: 37.470.1, in 1C). The
other data are shown in Figure 1. Treatment (SALINE,
EtOH, MDMA, EtOHþMDMA)Time (30, 60, 120, 180,
and 300min after injection)Day (days 1, 2, 3, and 4)
ANOVA showed all factors and interactions to be sig-
nificant. The Treatment effect (F 3/19¼ 15.7, po0.001) was
due to a temperature increase in MDMA and EtOHþ
MDMA rats (po0.001). The Time effect (F 4/76¼ 15.2,
po0.001) was due to temperatures that were significantly
higher, mainly 60, 120, and 180min after treatment, with the
highest level achieved at 60min (po0.05 at least). The Day
effect was due to body temperatures that were significantly
higher on day 1 or day 2 as compared to the subsequent
ones (po0.05). TreatmentTime interaction can be
explained by the peak that was observed at the postinjection
delay of 60min in MDMA and EtOHþMDMA rats. The
TreatmentDay interaction is due to the temperature
fluctuations in MDMA and EtOHþMDMA rats. The
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TimeDay interaction can be explained by the fact that, on
the longest postinjection delays, the overall temperature
reached weaker values on the last 2 days as compared to the
first two ones. Part of the TreatmentTimeDay interac-
tion is due to a temperature that, on day 1, was significantly
higher in MDMA rats as compared to EtOHþMDMA rats
on time points 1 (po0.05), 2 (po0.001), 3 (po0.05), and
4 (po0.05), not 5. This difference was not observed on
the subsequent days. Also, on time point 2 of day 2, the
temperature was significantly higher in EtOHþMDMA rats
as compared to MDMA rats (po0.05).
In summary, MDMA-induced hyperthermia was partly
prevented by ethanol coadministration, but only after the
first treatment.
Behavioral Data
T-maze alternation. There was no effect of treatment on
this behavioral measure (data not shown). The average
alternation rates were 74.075.2 (SALINE), 73.378.3
(EtOH), 80.075.2 (MDMA), and 66.779.4 (EtOHþ
MDMA).
Beam walking. The results are shown in Figure 2. ANOVA
showed an overall Treatment effect (F 3/37¼ 4.1, po0.05).
Multiple comparisons showed that the beam-walking scores
were significantly lower in EtOH, MDMA, and EtOHþ
MDMA rats as compared to control (po0.05). The means
among the three drug treatment groups were not signifi-
cantly different from each other.
Elevated plus maze. ANOVA of the number of arm entries
failed to show a significant Treatment effect (F 3/27 o1.0;
score in SALINE was 20.671.4). ANOVA also failed to show
a significant Treatment effect on other variables (percent
entries in open arms, F 3/27 o1.0; score in SALINE was
43.273.2; percent time on open arms, F 3/27o1.0; score in
SALINE was 34.475.5). Data are not illustrated.
Neurochemical Data
Norepinephrine concentration. The data are presented in
Table 1. In none of the brain regions did we observe a
significant effect of Treatment. There was a trend, however,
seen in the frontal cortex (F 3/29¼ 2.37, po0.1).
DA concentration. Mean concentrations are presented in
Table 1. ANOVA showed a significant Treatment effect in
the striatum (F 3/29¼ 3.1, po0.05) and the temporal cortex
(F 3/29¼ 3.8, po0.01). In the striatum, DA concentration
was significantly less in EtOHþMDMA as compared to
MDMA rats (po0.05). In EtOHþMDMA rats, the DA
concentration also tended to be less than in saline-treated
rats (p¼ 0.08). In the temporal cortex, the DA concentration
was significantly greater in EtOHþMDMA rats as com-
pared to the EtOH rats (po0.05), and tended to be greater
than in MDMA rats (p¼ 0.08). In the other regions, there
was no significant Treatment effect.
DOPAC concentration. The data are shown in Table 1.
ANOVA showed a significant Treatment effect in the
temporal cortex (F 3/29¼ 3.4, po0.05) and in the ventral
hippocampus (F 3/29¼ 4.2, po0.05). In the temporal
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Figure 1 Mean body temperature (meanþ SEM) at five delays (30, 60,
120, 180, and 300min) after injections of saline (SALINE; injection volume
7.5ml/kg), ethanol (EtOH; daily dose of 1.5 g/kg), (7)-3,4-methylenediox-
ymethamphetamine (MDMA; daily dose of 10mg/kg), or both EtOH and
MDMA (EtOHþMDMA; daily dose 1.5 g/kg and 10mg/kg, respectively). In
each panel, the dashed line indicates the average body temperature of all
rats measured 60min before treatment administration (SEM was
approximately 0.11C). Injections were made on four consecutive days
(1–4, respectively). To prevent an overload of statistical symbols in the
figure, only significant differences between MDMA and EtOHþMDMA
rats are indicated: $po0.05. On all 4 days, the temperature in MDMA and
EtOHþMDMA rats was significantly higher than that measured in SALINE
or EtOH rats. The difference between overall temperatures in SALINE and
EtOH rats was not significant.
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Figure 2 Beam-walking scores (meanþ SEM; maximal score¼ 12) in
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cortex, the concentration of DOPAC was significantly
elevated in EtOHþMDMA rats as compared to EtOH or
MDMA rats (po0.05 in each case). In the ventral
hippocampus, the concentration of DOPAC was signifi-
cantly reduced in EtOH and MDMA rats as compared to
their saline-treated counterparts (po0.05 in each case). In
the other regions, there was no significant Treatment effect.
5-HT concentration. The reader is directed to Figure 3. The
concentration of 5-HT was significantly affected in all
regions (F 3/29¼ 4.5, po0.01 or less). In the prefrontal
cortex, the concentration of 5-HT was significantly reduced
in EtOHþMDMA rats as compared to EtOH (po0.01); in
EtOH rats, the 5-HT concentration was also significantly
higher than in SALINE rats (po0.05). In the three other
cortical regions (frontal, temporal, occipital), the 5-HT
concentration was significantly lower in MDMA and EtOH
þMDMA rats as compared to SALINE rats (po0.05), and
in EtOHþMDMA rats as compared to MDMA (po0.05). In
the striatum, a significant reduction of the 5-HT concentra-
tion was found in MDMA and EtOHþMDMA rats as
compared to SALINE rats (po0.001 in each case). In the
septal region, the concentration of 5-HT was significantly
lower in EtOHþMDMA rats as compared to EtOH or
SALINE rats (po0.01); in MDMA rats, the reduction was
also significant (po0.05). Finally, in the dorsal hippocam-
pus, the concentration of 5-HT was significantly less in
MDMA and EtOHþMDMA rats as compared to SALINE
rats (po0.01 at least); in the ventral hippocampus, there
was a similar picture.
5-HIAA concentration. Data are shown in Figure 3. As the
overall profile of 5-HIAA levels was very comparable to that
of 5-HT levels, results are not described in detail.
Table 1 Concentration of Catecholamines in the Different Brain Structures of SALINE, EtOH, MDMA, and EtOH+MDMA Rats
(All Values Correspond to Means7SEM and are Given in pg/mg Irradiated Tissue)
Group
Catecholamine/brain region SALINE, n¼8 EtOH, n¼10 MDMA, n¼ 8 EtOH+MDMA, n¼ 7
Norepinephrine
Prefrontal cortex 10278 10974 9973 10977
Frontal cortex 9177 7574 9276 8275
Temporal cortex 9578 7677 8276 8776
Occipital cortex 5974 5172 5775 5473
Striatum 77710 4977 6672 5275
Septum 498749 395739 397720 408746
Dorsal hippocampus 11978 9477 10975 10776
Ventral hippocampus 20976 189726 19277 17679
Dopamine
Prefrontal cortex 5757118 5777171 4827147 5727123
Frontal cortex 140725 110713 146721 172723
Temporal cortex 95717 49713 6279 108718#
Occipital cortex 1571 2172 2577 2272
Striatum 23547220 21077138 25687121 17387286$
Septum 858780 687779 9947175 6847128
Dorsal hippocampus 2974 2774 3977 2273
Ventral hippocampus 2472 33710 2373 1973
DOPAC
Prefrontal cortex 76717 73717 67718 73715
Frontal cortex 3377 2973 4278 4578
Temporal cortex 1672 1272 1372 2174#,$
Occipital cortex 471 671 671 671
Striatum 364751 330716 385725 327732
Septum 183719 150713 224737 14172
Dorsal hippocampus 1671 1771 2071 1571
Ventral hippocampus 3571 2174* 2074* 2874
*Significantly different from SALINE, po0.05.
#Significantly different from EtOH, po0.05.
$Significantly different from MDMA.
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5-HIAA/5-HT ratio. These data are not illustrated. ANOVA
showed a significant Treatment effect on the 5-HIAA/5-HT
ratio only in the septal region and in the dorsal
hippocampus (F 3/29¼ 3.0 and 8.8, respectively, po0.05).
In the septal region, multiple comparisons failed to show
any significant difference between two conditions: the ratio
tended to be smaller in EtOHþMDMA rats as compared to
EtOH rats and larger in EtOH rats as compared to SALINE
ones (po0.10). In the dorsal hippocampus, the ratio was
significantly smaller in EtOHþMDMA rats as compared to
each of the three other groups (po0.05 at least). In MDMA
rats, this ratio was also significantly smaller than in EtOH
rats (po0.05).
5-HT Release
Accumulation of [3H]-5-HT by cortical and hippocampal
slices. Data are shown in Table 2. ANOVA of the [3H]5-HT
accumulation showed no significant Treatment effect,
whether in the cortex (F 2/27 o1.0) or the hippocampus
(F 3/27 o1.0).
Baseline outflow of tritium in cortical and hippocampal
slices. Data are presented in Table 2. ANOVA of baseline
outflow of tritium from cortical or hippocampal slices
showed no significant Treatment effect on absolute (nCi) or
the relative (percent of accumulated [3H]) outflow (F 3/27
always lower than 2.2, p40.10).
Electrically evoked overflow of tritium in cortical and
hippocampal slices. The data are shown in Table 2. ANOVA
of the electrically evoked release from cortical slices
showed a significant Treatment effect on absolute values
(F 3/27¼ 3.69, po0.05), but not on relative ones
(F 3/27¼ 2.1). This Treatment effect was due to significantly
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Figure 3 Concentration (meanþ SEM) of 5-HT (a) and 5-HIAA (b) in
various regions of the cortex (PFR: prefrontal; FRPT: frontoparietal; TP:
temporal; OCC: occipital) and other brain regions (STR: striatum; SPT:
septum; DH: dorsal hippocampus; VH: ventral hippocampus) in the four
groups of rats. Group abbreviations as in Figure 1. *Significantly different
from SALINE, po0.05; #significantly different from EtOH, po0.05.
Table 2 Accumulation of [3H]5-HT, Basal Outflow and Electrically Evoked Overflow of Tritium in Cortical and Hippocampal Slices from
SALINE, EtOH, MDMA and EtOH+MDMA Rats (All Values are Means7SEM Outflow and Overflow are Indicated in Absolute Values or as
a Percentage of the Tritium Accumulated in Each Slice)
Group
Brain region/variable SALINE, n¼ 7 EtOH, n¼ 8 MDMA, n¼7 EtOH+MDMA, n¼9
Cortex
[3H]5-HT accumulation (pmol/slice) 0.63470.03 0.64670.04 0.69070.03 0.69770.03
Baseline [3H]5-HT outflow (nCi) 0.42970.03 0.48270.06 0.43070.03 0.44170.02
Baseline [3H]5-HT outflow in % of [3H] accumulation 2.36070.16 2.22070.11 2.14670.06 2.19270.08
Electrically evoked [3H]5-HT outflow (nCi) 0.75670.03 0.89970.06 0.98270.09* 1.04370.07*
Electrically-evoked [3H]5-HT outflow in % of [3H] accumulation 4.18670.28 4.86370.27 4.95070.32 5.2370.33
Hippocampus
[3H]5-HT accumulation (pmol/slice) 0.77970.06 0.81370.06 0.76170.02 0.73070.05
Baseline [3H]5-HT outflow (nCi) 0.45670.03 0.50970.04 0.42170.02 0.42070.02
Baseline [3H]5-HT outflow in % of [3H] accumulation 2.02270.06 2.13970.06 1.90270.05 2.05570.07
Electrically evoked [3H]5-HT outflow (nCi) 1.03370.09 1.00270.07 1.04370.03 1.12470.06
Electrically evoked [3H]5-HT outflow in % of [3H] accumulation 4.56470.12 4.33070.08 4.75670.15 5.31670.20*,#,$
*Significantly different from SALINE, po0.05.
#Significantly different from EtOH, po0.05.
$Significantly different from MDMA, po0.05.
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larger evoked release in MDMA and EtOHþMDMA rats as
compared to SALINE rats (po0.05). In the hippocampus,
there was a significant Treatment effect on the relative
(F 3/27¼ 8.2, po0.001), but not on absolute release (F 3/27
o1.0). This effect was due to a significantly larger relative
release in EtOHþMDMA rats as compared to SALINE
(po0.01), EtOH (po0.001), and MDMA (po0.05) rats.
Effects of CP 93,129 in cortical and hippocampal slices.
Data are shown in Figure 4. In cortical slices, ANOVA
showed no significant overall Treatment effect (F 3/27¼
1.9). There was a significant Concentration effect (F 3/81¼
1105.2, po0.001). The interaction between both factors
tended to be significant (F 9/81¼ 1.9, p¼ 0.06). The
Concentration effect can be explained by a concentration-
dependent decrease of the release. The release was
significantly larger in MDMA and EtOHþMDMA rats than
in SALINE rats (po0.05 in each case) at the concentration
of 0.001mM, and in EtOHþMDMA rats at the concentra-
tion of 0.01 mM (po0.01).
In hippocampal slices, ANOVA showed significant effects
of Treatment (F 3/27¼ 7.6, po0.001) and Concentration
(F 3/81¼ 999.5, po0.001), but not the interaction (F 9/81
o1.0). The Treatment effect was due to inhibitory effects of
CP-93,129 on 5-HT release that were significantly more
pronounced in EtOHþMDMA rats than in the other ones
(po0.05). The Concentration effect can be explained by a
concentration-dependent decrease of the release. Multiple
comparisons showed that the release in EtOHþMDMA rats
was significantly lower than in each of the three other
groups (po0.05 at least), regardless of the concentration.
Effects of methiotepin in cortical and hippocampal slices.
Data are shown in Figure 4. In cortical slices, ANOVA
showed no significant overall Treatment effect (F 3/27¼
1.6). There was a significant concentration effect (F 1/27¼
388.7, po0.001), but no interaction (F 3/27 o1.0). At the
low concentration of methiotepin, the overall release was
increased by about 30% as compared to control, whereas at
the highest one, it was increased by 83%.
In hippocampal slices, ANOVA showed significant Treat-
ment (F 3/27¼ 5.7, po0.01), Concentration (F 1/27¼ 580.2,
po0.001), and interaction (F 3/27¼ 4.2, po0.05) effects.
The Treatment effect was due to the facilitatory effect of
methiotepin, which was smaller in EtOHþMDMA rats than
in the rats from the other groups (po0.05). The Concen-
tration effect was due to a larger increase at the highest
concentration (þ 78%). Multiple comparisons showed that
for each concentration, the release in EtOHþMDMA rats
was significantly lower than in the other groups (po0.05).
DISCUSSION
The present results confirm that repeated MDMA intoxica-
tion induces alterations in 5-HT and 5-HIAA content in
most brain regions assessed. They also demonstrate that
combination of ethanol and MDMA does not result in
behavioral or neurochemical effects different from those of
MDMA alone. The only behavioral alteration found was on
beam-walking performance when rats had been given
ethanol and/or MDMA, with no additive or synergistic
effects between both drugs. At 3–6 weeks after the combined
treatment with ethanol and MDMA, lasting changes in the
hippocampal modulation of 5-HT release were evident: in
the presence of CP 93,129 or methiotepin, the evoked
tritium release was significantly lower in EtOHþMDMA
rats. To our knowledge, this is the first demonstration that
several weeks after its administration, the combination of
MDMA with ethanol alters the possibly autoreceptor-
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Figure 4 Effects of the autoreceptor agonist CP 93,129 (left panel) or
the nonselective 5-HT1 receptor antagonist methiotepin (right panel) on
the electrically evoked release of [3H]5-HT in cortical (top) and
hippocampal (bottom) slices from rats of the four groups. Group
abbreviations as in Figure 1. Data are the mean (þ SEM) evoked overflow
expressed as a ratio (Sn/S1), and subsequently normalized for each
concentration (0.001–1.0mM) by computing the percent of control values
(no drug added to the superfusate). The dashed lines indicate the control
level (no change of the release). The inhibition of the evoked release was
significant for concentrations of 0.01 to 1.0 mM in both the cortex and the
hippocampus. *Significantly different from SALINE, po0.05; #significantly
different from EtOH, po0.05; $significantly different from MDMA, po0.05.
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mediated modulation of 5-HT release in the rat hippocam-
pus, without producing overt serotonergic toxicity or
behavioral changes compared to those found after MDMA
alone.
Acute Effects of EtOH and/or MDMA Intoxications
We recently reported that MDMA-induced hyperactivity
and hyperthermia (Cassel et al, 2004) did not change in
magnitude when the treatment was repeated at three other
occasions, 24 h apart. Furthermore, ethanol treatment had
no effect on activity scores, but resulted in a small but
significant hypothermia (about 0.51C) that showed some
tolerance on subsequent days. When coadministered with
MDMA, ethanol potentiated the locomotor response and
protected against hyperthermia. Prevention of hyperther-
mia, however, was observed only after the first treatment, as
in the present experiment. This limited prevention might
have resulted from: (1) tolerance to the hyperthermic effects
of MDMA (Marston et al, 1999) or (2) tolerance to the effect
of ethanol, perhaps specifically in the presence of MDMA.
The pharmacokinetic and/or pharmacodynamic mechan-
isms underlying these ethanol-induced effects remain as yet
unknown. In mice given ethanol and MDMA, the striatal
concentration of MDMA was about four times larger than in
controls, suggesting that ethanol may interfere with (i)
MDMA metabolism, (ii) penetration of MDMA into the
brain, or (iii) removal of MDMA from the brain (Johnson
et al, 2004). Should the same be true in rats, and as the
effects of ethanol on the locomotor (Cassel et al, 2004); (see
also Rezvani et al, 1992) and pyretic consequences of
MDMA were in opposite directions, one pharmacokinetic
explanation could be that MDMA (or a particular metabo-
lite) was involved in one of the effects (hyperlocomotion),
while a metabolite (or a further metabolite) would be
involved in the other one (hyperthermia). Dissociation
between the effects of MDMA and its metabolites has not
been demonstrated for behavioral or physiological vari-
ables, but were described for toxicity vs 5-HT release.
Indeed, direct injection of MDMA into the hippocampus
increases 5-HT release without any toxicity to serotonergic
terminals (Esteban et al, 2001). Further experiments are
needed to understand the mechanism(s) involved in
ethanol-induced alterations of MDMA actions.
Long-Term Effects of EtOH and/or MDMA on
Monoaminergic Markers
Now that we have shown that ethanol modulates the acute
effects of MDMA, the long-term effects of ethanol–MDMA
combinations are of obvious interest, particularly in terms
of toxicity. Acute neurochemical and neuropharmacological
effects of ethanol are well known, but especially compelling
are the consequences after chronic intoxication or during
withdrawal (eg Darstein et al, 2000; LeMarquand et al, 1994;
Thielen et al, 2004). As to long-term effects of shorter
periods of ethanol treatment, however, the literature is, to
our knowledge, rather scanty. A few reports show that brief
periods of alcohol intoxication (eg binge exposure) may
result in damage in the olfactory bulbs, the entorhinal
cortex, and the dentate gyrus (Crews et al, 2000; Zou et al,
1996). Recently, Vasconcelos et al (2003) reported that, in
rats, ethanol administered daily for 7 days did not alter
striatal 5-HT concentration 48 h after the last treatment. In
the present study, we do not know yet how to account for
the significant increase in 5-HT concentration in the
prefrontal cortex of rats given only ethanol, but it is
interesting to note that in the EtOH and MDMA group, this
increase was not observed. Ethanol may interfere with the
metabolism of tryptophan (eg Badawy, 1999), as well as alter
the sensitivity of presynaptic 5-HT1A receptors (Esteban
et al, 2002), and these two findings might be considered
consistent with our observations.
Although the serotonergic toxicity of MDMA may vary as
a matter of species, strain, and other factors (eg Green et al,
2003), serotonergic alterations are found in rats already 1
week after intoxication (eg Schmidt et al, 1987). These
effects persist for several months, despite protracted
recovery (Sabol et al, 1996; Scanzello et al, 1993). As our
rats were killed 3 weeks after the last drug treatment,
recovery of neurochemical parameters was probably
limited. Keeping in mind that neurochemical markers are
indirect markers of neurotoxicity (Green et al, 2003), and
that MDMA toxicity for serotonergic neurons has been
recently questioned (Wang et al, 2004, but see Schmued,
2003), our data are in line with reports showing that MDMA
reduced 5-HT and 5-HIAA concentrations in several brain
regions (Sabol et al, 1996). In addition to changes in the
cortex, hippocampus, and striatum, we found serotonergic
alterations in the septal region. This finding is at variance
with the report by Sabol et al (1996), although in line with
the fact that the lateral septum has dense 5-HT innervation
(Dinopoulos et al, 1993). The lack of serotonergic effects of
MDMA in the prefrontal cortex, another important target
of the serotonergic system (eg Steinbusch, 1981), is also
surprising. In a recent report, Clemens et al (2004)
demonstrated serotonergic toxicity of MDMA in the
prefrontal cortex, but only in rats given a high dose
(4 5mg/kg/day on 2 successive days). It is also note-
worthy that the reduction of serotonergic markers was
about 16% in the prefrontal cortex, but twice that
magnitude in brain regions such as the striatum or the
hippocampus, suggesting that the serotonergic innervation
of the prefrontal cortex might be less sensitive to MDMA
toxicity or undergo faster recovery. Against this possibility
is the report by McGregor et al (2003), who, 3 months after
a high dose of MDMA (4 5mg/kg/h over 4 h), found that
the MDMA-induced decrease of 5-HT concentration was
larger in the prefrontal cortex than in the hippocampus.
Strain differences (Green et al, 2003) and post-MDMA
delays might contribute to such discrepancies between
studies. In addition, part of the variability in the MDMA
toxicity might also be linked to differential vulnerability/
recovery of projections from the median or dorsal raphe´
(eg Molliver et al, 1990).
As serotonergic toxicity depends on MDMA-induced
hyperthermia (but see McGregor et al, 2003) and alcohol
attenuates MDMA-induced hyperthermia (eg Cassel et al,
2004; Johnson et al, 2004), it might seem surprising that
serotonergic functioning was similar for MDMA and EtOH
þMDMA-treated rats. One explanation might be that the
MDMA-induced hyperthermia was prevented only by the
first injection of ethanol, that is, that the similarity in
alteration of serotonergic function in MDMA and EtOHþ
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MDMA rats can be accounted for by tolerance to ethanol in
its protective effects. Studies employing conditions in which
such tolerance is not observed, for example, by spacing out
intoxication days, would help to elucidate the problem.
Long-Term Effects of EtOH and/or MDMA on Behavior
Acutely, ethanol alters memory (eg Givens, 1995), motor
coordination (eg Gallate et al, 2003; but see Metz et al,
2003), and anxiety-related behaviors (eg Gallate et al, 2003;
Langen et al, 2002; Ryabinin, 1998). Beside hyperlocomo-
tion and hyperthermia, MDMA alters motor coordination
(Marston et al, 1999), anxiety (Bhattacharya et al, 1998;
Morley and McGregor, 2000; Sumnall et al, 2004), and
cognitive functions (Braida et al, 2002; Ho et al, 2004;
Marston et al, 1999; but see Ricaurte et al, 1993). With
exception of the effects described by Cassel et al (2004; see
also Rezvani et al, 1992), the acute behavioral effects of both
drugs in combination were not studied yet in animals. In
the long-term, chronic ethanol treatment may alter
cognitive functions (Beracochea and Jaffard, 1991), even
after withdrawal (eg Arendt, 1994), and withdrawal from
ethanol is anxiogenic (File et al, 1993). MDMA intoxication
may produce changes in anxiety-related (McGregor et al,
2003; Morley et al, 2001) and, to some extent, cognitive (eg
Marston et al, 1999) behaviors; however, there are no data
on long-term effects of both drugs in combination.
Obernier et al (2002) demonstrated that a 4-day binge
ethanol exposure induced limbic damage and long-term
impairment in cognitive function: intoxicated rats showed
normal reference- and working-memory performance in a
water-maze task, but were impaired in reversal learning. In
the present study, we found a deficit only in the beam-
walking test. This task is extremely sensitive to alterations
in balance or sensory-motor coordination. For instance, rats
with partial lesions of Purkinje cells (eg Thach et al, 1992)
show impaired beam walking (eg Lehmann et al, 2000 and
unpublished data). One possible reason for the persistence
of effect is neuronal loss. Owing to the dose of ethanol used,
we believe this is unlikely. Repeated ethanol treatment also
induces lasting dysfunction of cerebellar neurons. This
possibility would deserve further investigation, but appears
compatible with findings showing ethanol-induced dys-
function of Purkinje cells (eg Gruol et al, 1997; Wang et al,
1999).
Rats given MDMA also showed impaired beam-walking
performance. Serotonergic depletion may alter balance or
sensory–motor coordination (Lehmann et al, 2000; but see
Lehmann et al, 2002). MDMA might also directly affect
cerebellar (eg granule or Purkinje) cells or perturb their
interactions with serotonergic terminals. Thus, it is possible
that beam-walking deficits in MDMA-treated rats reflected a
long-term alteration of such interactions. Future studies
relying upon morphological approaches should contribute
to progress on this issue.
MDMA was found to induce anxiety in the long term
(Morley et al, 2001). This anxiety was presumably linked to
serotonergic toxicity. In the present study, there was clear
evidence for serotonergic depletion, indicating that the lack
of MDMA-induced anxiety was not due to lack of
serotonergic alterations. It is possible, however, that our
serotonergic effects were less pronounced than in the
Morley et al study, who, unfortunately, did not report on
their serotonergic effects. Despite different testing condi-
tions (eg red light vs white light), both test situations
yielded comparable percent time spent in the open arms
in controls (about 33%). A last difference was on the
postinjection delay, which was of 19 days herein against 3
months in the study by Morley et al (2001). Thus, it could
be that some of the alterations induced by MDMA require
some delay before anxiety-related behaviors appear. This
speculation seems in line with observations from the
literature: long-term anxiogenic effects of MDMA (but see
Mechan et al, 2002) were found at postintoxication delays
above 4 weeks (Bull et al, 2004; Gurtman et al, 2002; Morley
et al, 2001, see also McGregor et al, 2003) against no or
small effects at shorter delays (eg Ho et al, 2004; Sumnall
et al, 2004).
Long-Term Effects of EtOH and/or MDMA on Evoked
5-HT Release and Its Modulation by Autoreceptors
Acute alcohol intoxication may influence 5-HT release (eg
Bare et al, 1998; Thielen et al, 2002), and so does MDMA
(Green et al, 2003 for a review). To our knowledge, the long-
term serotonergic effects of a short period of repeated
ethanol intoxication are mostly unknown. As to MDMA,
several findings pointing towards a reduction of the release
of 5-HT after MDMA treatment contrast with our present
results (Gartside et al, 1996; Matuszewich et al, 2002; Series
et al, 1994; Shankaran and Gudelsky, 1999). Indeed, in rats
given MDMA alone, the 5-HT and 5-HIAA concentrations
were reduced in various brain regions, but accumulation of
[3H]5-HT in cortical and hippocampal slices, baseline
outflow, and electrically evoked overflow of [3H]5-HT were
close to normal.
This is a first important result of our release experiments.
If one omits their findings in the frontal cortex, our data
agree with those of Gartside et al (1996). These authors
showed that, 2 weeks after intensive treatment with MDMA,
(i) the firing activity of dorsal raphe´ neurons was normal,
(ii) the basal release of 5-HT assessed by means of in vivo
microdialysis was normal in the frontal cortex and the
hippocampus, and (iii) the stimulation of the dorsal or
the medial raphe´ induced an increased 5-HT release in the
hippocampus. Interestingly, this stimulated increase was
not different between MDMA and saline-treated rats. Thus,
despite a marked 5-HT depletion in various brain regions,
and particularly in the regions in which evoked 5-HT
release has been studied, it appears that normal serotoner-
gic functions can be detected. Gartside et al (1996)
attributed this to a capability of unaltered serotonergic
terminals to increase their releasable 5-HT pool. This
interpretation is compatible with enhanced neurotransmit-
ter release properties described in other lesion models
(eg Suhr et al, 1999). Also the modulation of the 5-HT
release via autoreceptors, which are of the 5-HT1B subtype,
was found to be normal in MDMA-treated rats. Although
5-HT1B receptors may take part in the acute locomotor
effects of MDMA (eg Bankson and Cunningham, 2002;
Callaway and Geyer, 1992; McCreary et al, 1999), these
effects most probably involve 5-HT1B receptors on other
neurons, that is, 5-HT1B heteroreceptors. Concerning
autoreceptors, we show that their functional characteristics
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are normal despite long-term alterations of tissue-5-HT and
5-HIAA concentrations.
The second important finding from the release experi-
ments is the apparent change in the modulation of 5-HT
release in the hippocampus of rats given ethanol and
MDMA in combination. Our data clearly show that the
evoked overflow of 5-HT (in percent of tissue-3H) in
the hippocampus was slightly but significantly increased in
the EtOHþMDMA group as compared to the rats treated
with saline or EtOH alone (Table 2). This increase in the
relative amount of the evoked 5-HT release was observed
despite a decrease in hippocampal tissue concentrations of
both 5-HT and 5-HIAA (Figure 3). Taken together, these
two observations suggest changes in the modulation of 5-
HT release at the serotonergic axon terminals, changes that
appear to lead to a greater amount of transmitter release per
individual axon terminal.
Such alterations might either reflect a reduction of
inhibitory control mechanisms or an enhancement of
facilitatory influences due to the combined treatment with
MDMA and EtOH. Interestingly, however, in the hippo-
campus of these rats, the main presynaptic inhibitory
receptor, the 5-HT1B autoreceptor, appeared to be not less,
but even significantly more sensitive (Figure 4). Also, in
previous studies using rats with fimbria–fornix lesions of
hippocampal afferent fibers, an increase in the sensitivity of
the 5-HT1B autoreceptor was observed (Jackisch et al, 1999).
Similar lesions cause, however, a significant serotonergic
denervation and lead to a decrease of hippocampal 5-HT
content and 5-HT release during ongoing stimulation.
Therefore, it was possible to show (Jackisch et al, 1999)
that the higher potency of the 5-HT1B autoreceptor agonist
was only apparent and caused by the diminished competi-
tion with the endogenous agonist 5-HT in the vicinity of the
autoreceptor (‘biophase concentration of 5-HT’). Although
a similar interpretation for the present data is further
supported by the decrease of the facilitatory effect of
the nonselective 5-HT receptor antagonist methiotepin
(Figure 4, see also a similar picture in Jackisch et al,
1999), it contrasts with the relative increase of 5-HT release
at S1 (Table 2), an observation that was, however, also made
in rats with fimbria–fornix lesions (Jackisch et al, 1999). In
addition, if true, this hypothesis would suppose that
changes found in EtOHþMDMA rats should also be
present in MDMA rats: this was not the case.
One possibility to account for the apparently paradoxical
findings with CP 93,129 and methiotepin would be that
methiotepin may alter the release of another transmitter
that (i) is not influenced by a drug acting on 5-HT1B
receptors, (ii) might interfere with the serotonergic terminal
in a way that would oppose to the facilitatory effects of
methiotepin on evoked 5-HT release, and (iii) would
activate an inhibitory heteroreceptor present on the
serotonergic terminal, and which is upregulated after
combined ethanol and MDMA treatment. Based on our
current state of knowledge, it is not possible to propose a
particular receptor. Possible candidates include GABAA,
GABAB, and NMDA receptors (eg Vizi and Kiss, 1998). It
could also be that EtOHþMDMA treatment has resulted in
an increase of presynaptic facilitatory influences on 5-HT
release, which might involve AMPA or 5-HT3 receptors
(eg Vizi and Kiss, 1998).
Conclusion
The present results show that repeated treatment with
ethanol or/and MDMA produces lasting effects that are
manifest in behavior and neurochemistry. Some of these
effects may be attributed (i) to MDMA alone, that is,
reduced concentrations of 5-HT and 5-HIAA in various
brain regions, although 5-HT release capabilities appear
normal, (ii) to MDMA alone or to ethanol alone, perhaps by
the way of different mechanisms leading to comparable
consequences, that is, reduced sensory–motor coordination
capabilities, or (iii) specifically to the combination of both
drugs, that is, alteration of mechanisms involved in the
modulation of 5-HT release in the hippocampus. They also
demonstrate that ethanol neither attenuates nor exacerbates
effects of MDMA on (i) behavior, or, (ii) levels of 5-HT and
5-HIAA in the cortex and the hippocampus. This is the first
study to address delayed effects of MDMA and EtOH, singly
and in combination. We conclude that the mechanisms
involved in presynaptic modulation of 5-HT release in the
hippocampus may be particularly sensitive to this combina-
tion. Our findings also suggest that when the recreational
use of ecstasy is combined with ethanol, it is possible that
the long-term psychopathological problems reported by
ecstasy usersFwhich are usually attributed to the 5-HT
depleting effect of MDMAFmay not be caused solely by the
consumption of MDMA. Indeed, we have shown that the
combination of MDMA with ethanol may have some long-
term consequences on serotonergic functions that MDMA
alone does not account for.
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